This review covers Pfizer's worldwide business and provides information on our activities for the year ending on December 31, 2020. It describes key dimensions of our purpose, strategy and performance. This year, the scope of Pfizer’s reporting has expanded to include more robust analysis of trends and strategies for addressing Environment, Social and Governance (ESG) key performance indicators. The ESG Report, in which this new information is supplied, is available for download via link in the footer of this report.
Data in this review and associated ESG Report covers the calendar year from January 1 to December 31, 2020, unless otherwise stated.
This Annual Review contains forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, dividend and share repurchases, reorganizations, plans for and prospects of our acquisitions, dispositions and other business-development activities and our ability to successfully capitalize on these opportunities, manufacturing and product supply, our efforts to respond to COVID-19, including the Pfizer-BioNTech mRNA vaccine for COVID-19 (BNT162b2) and our investigational protease inhibitor, and our expectations regarding the impact of COVID-19 on our business, operations and financial results that are subject to substantial risks and uncertainties. We cannot guarantee that any forward-looking statement will be realized. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. A further list and description of risks, uncertainties and other matters can be found in Pfizer's Annual Report on Form 10-K for the year ended December 31, 2020, and in Pfizer's subsequent reports on Form 10-Q, in each case including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in Pfizer's subsequent reports on Form 8-K. These reports are available on our website at www.pfizer.com and on the U.S. Securities and Exchange Commission's (SEC) website at www.sec.gov. The forward-looking statements in this Annual Review speak only as of the original date of this Annual Review, and we undertake no obligation to update or revise any of these statements as the result of new information or future events or developments.
Chairman and CEO Albert Bourla reflects on a year of breakthrough innovation at Pfizer
Science illuminates a path forward for patients across the world
Courage, excellence, equity and joy guide all our endeavors
2020 by the numbers
Read the latest information about Pfizer’s COVID-19 vaccine on Pfizer.com.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.
Copyright © 2020-2021 Pfizer Inc.
All rights reserved